Jane Street
KALV

Jane Street’s KalVista Pharmaceuticals KALV Stock Holding History

Jane Street’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$260K Sell
12,900
-1,600
-11% -$25.8K ﹤0.01% 9553
2025
Q4 		$234K Buy
+14,500
New +$192K ﹤0.01% 9390
2024
Q2 		– Sell
-499,000
Closed -$5.92M – 9807
2024
Q1 		$5.92M Buy
+499,000
New +$6.65M ﹤0.01% 2395
2021
Q4 		– Sell
-10,900
Closed -$190K – 10474
2021
Q3 		$190K Sell
10,900
-2,700
-20% -$54.7K ﹤0.01% 8889
2021
Q2 		$326K Buy
+13,600
New +$356K ﹤0.01% 8006

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street's KALV Position: Q1 2026 in Review

Jane Street sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 31,608 shares — an estimated $509K sold.

Jane Street first reported a position in KALV in Q2 2021 and held it in 12 quarters. The position peaked at $4.09M in Q1 2024. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Jane Street reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 31,608 KalVista Pharmaceuticals shares in Q1 2026, an estimated $509K.
  • Jane Street first reported a position in KalVista Pharmaceuticals in Q2 2021 and held it in 12 quarters.
  • Jane Street's KalVista Pharmaceuticals position peaked at $4.09M in Q1 2024.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.